Curated News
By: NewsRamp Editorial Staff
September 18, 2025
Kairos Pharma's Prostate Cancer Therapy Shows Breakthrough 13+ Month Survival
TLDR
- Kairos Pharma's ENV105 combination therapy offers investors a competitive edge with median progression-free survival exceeding 13 months versus standard 3.7 months in prostate cancer.
- ENV105 targets CD105 protein to reverse drug resistance, combining with apalutamide to achieve PSA declines in 7 of 9 patients with no dose-limiting toxicities observed.
- This breakthrough therapy extends survival for metastatic prostate cancer patients, reducing treatment resistance and improving quality of life for those facing limited options.
- Kairos Pharma's antibody therapy defies cancer drug resistance, showing remarkable 13+ month survival in patients who previously had only 3.7 months expected.
Impact - Why it Matters
This development represents a potential paradigm shift in treating metastatic castration-resistant prostate cancer, one of the most challenging forms of prostate cancer with limited treatment options. For patients facing this aggressive disease, the combination therapy's demonstrated progression-free survival of over 13 months—more than triple the current standard—could significantly extend life expectancy while maintaining quality of life. The well-tolerated nature of the treatment without dose-limiting toxicities addresses a critical need for therapies that are both effective and manageable for patients undergoing cancer treatment. This breakthrough could eventually benefit thousands of patients worldwide and represents important progress in overcoming treatment resistance, a major hurdle in oncology.
Summary
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has announced highly promising interim efficacy data from its ongoing Phase 2 trial of ENV105 (carotuximab) in metastatic castration-resistant prostate cancer. The combination therapy of ENV105 and apalutamide demonstrated remarkable results, achieving median progression-free survival exceeding 13 months among eight evaluable patients—far surpassing the trial's target of a 45% improvement over the standard 3.7 months for second- or third-line hormone therapy. With five patients still on treatment and seven of nine showing significant declines in prostate-specific antigen levels, the treatment also proved well-tolerated with no dose-limiting toxicities observed.
Based in Los Angeles, California, Kairos Pharma leverages structural biology to develop oncology therapeutics that overcome drug resistance and immune suppression in cancer. Their lead candidate, ENV105, is an innovative antibody targeting CD105—a protein identified as a key driver of resistance to various cancer treatments. By reversing drug resistance through CD105 targeting, ENV105 aims to restore the effectiveness of standard therapies across multiple cancer types. The company is currently conducting additional trials, including a Phase 1 study for lung cancer, addressing significant unmet medical needs in oncology.
The news was distributed through BioMedWire, a specialized communications platform focused on biotechnology and life sciences developments. As part of the Dynamic Brand Portfolio within IBN, BioMedWire provides comprehensive distribution services including wire solutions, article syndication to over 5,000 outlets, enhanced press release features, and social media distribution to millions of followers. This ensures that groundbreaking developments like Kairos Pharma's clinical trial results reach investors, journalists, and the general public effectively, cutting through today's information overload to deliver impactful medical news.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma's Prostate Cancer Therapy Shows Breakthrough 13+ Month Survival
